MarketInOut Stock Screener Log In | Sign Up
 

Aligos Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/02/2026
Aligos Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization34.59 mln
Float5.31 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

6.75
Highly suspicious

1-Year Forecast

52.38
Transformational upside

Relative Strength

89 / 100
Strongly outperforming

Debt / Equity

0.11
Very low leverage

Pre-Tax Margin

-231%
Severely loss-making

Business Description

Aligos Therapeutics is a clinical-stage company working to develop new medicines for patients with serious liver and viral diseases that currently have limited treatment options. Founded in 2018 and based in South San Francisco, the company has several drug candidates advancing through clinical trials, targeting conditions such as fatty liver disease, obesity, hepatitis B, and coronavirus infections. Aligos works alongside research partners including Emory University and KU Leuven to support its drug discovery and development efforts.

Key Fundamentals

EPS-7.47
ROE-131
RPS3.03
ROIC-520
ROA-81.88
EBITDA, mln-75.96
EV / EBITDA-0.21
EV / EBIT-0.21
Revenue, mln31.52
EV / Revenue0.52

Quote Details

Last 5.54
Change 0.04 (0.73%)
Open 5.58
Volume 28,977
Turnover 160,533
Average Volume 43,273

Financial Ratios

Pre-Tax Profit Margin-231
Leverage Ratio2.08
Current Ratio2.19
Price / Book1.35
Price / Tangible Book1.35
Debt / Equity0.11
Price / Sales2.29

Financial Strength

Altman Z-Score-15.85
Piotroski F-Score 3 / 9
Beneish M-Score6.75
1-Year Target Price52.38
Short Ratio11.92
Short % of Float13.15

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.54% 77 / 100   
1 Month -10.79% 21 / 100   
2 Months -0.54% 53 / 100   
6 Months -30.49% 15 / 100   
1 Year -46.16% 18 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us